View Older Stories View More Recent Stories
-
GoodRx offers Eli Lilly's new oral GLP-1 drug at $149 monthly
-
Lilly launches Foundayo oral GLP-1 weight loss pill in US market
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald Ahead of Foundayo Launch
-
AC Immune amends Lilly collaboration for tau drug development
-
Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
-
Eli Lilly (LLY) PT Raised to $1,294 at BofA Securities
-
Leerink Partners reiterates Outperform on Eli Lilly (LLY) following orforglipron approval
-
Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO tells CNBC
-
Truist Securities Reiterates Eli Lilly (LLY) at Buy on Foundayo approval, 'remain bullish on Lilly'
-
FDA approves Foundayo weight loss pill in record 50 days
-
Barclays on Eli Lilly (LLY): Centessa a 'sensible tuck-in' for neuroscience division
-
Eli Lilly & Co. (LLY) call put ratio 2.8 calls to 1 put after acquiring Centessa (CNTA)
-
BMO Capital on Eli Lilly (LLY): Centessa deal positive for shares; 'diversifying business ahead of any major LOEs'
-
Centessa shares surge after Lilly unveils $6.3 billion takeover deal
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Lilly partners with Insilico Medicine in AI drug discovery deal
-
Eli Lilly (LLY) PT Lowered to $1,163 at Guggenheim
-
Should you buy the dip in Novo Nordisk stock? Wall Street analyst answers
-
Lilly presents four-year data for EBGLYSS in atopic dermatitis study
-
Morgan Stanley on Eli Lilly (LLY) following scripts: 'We see ~6% upside to '26 M+Z ests'
-
Jefferies on Eli Lilly (LLY) competition: Oral Wegovy's TRx came in at ~94.7k on IMS & ~80.1k on Symphony
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put
-
Lilly gets FTC clearance for Innovent Biologics acquisition
-
Takeda, Lilly rejected by Supreme Court on Actos fraud lawsuit
-
Jefferies: Oral Wegovy Outpacing Injectables; Lilly (LLY) Well-Positioned Ahead of April PDUFA
-
India's Eris Lifesciences launches generic semaglutide at $13.8 per month
-
Leerink Partners on Eli Lilly (LLY) following Retatrutide data
-
BMO on Eli Lilly (LLY): 'Triple Agonist Turns Double Play - Extending Positive Results to Both T2D and OA'
-
Morgan Stanley on Eli Lilly (LLY): retatrutide weight loss data 'encouraging,' but offset by GI adverse events
-
Truist Securities on Eli Lilly (LLY): retatrutide ph3 results 'favorable' but similar data to Mounjaro
-
Wolfe Research on Eli Lilly (LLY): ph3 retratrutide results point to potential 'best-in-class' weight loss
-
UBS Reiterates Buy Rating on Eli Lilly (LLY) Following Strong Q4, Upside Guidance
-
HSBC downgrades Eli Lilly, says shares are 'priced to perfection'
-
HSBC Downgrades Eli Lilly (LLY) to Reduce
-
Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
-
RBC: 'Our focus for LLY remains on the pending Orfo approval and subsequent launch'
-
Jefferies Reiterates Buy Rating on Eli Lilly (LLY): 'early oral Wegovy launch is directionally encouraging'
-
Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug
-
Hims & Hers hires ex-Eli Lilly PR chief Beiser as top communications officer
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
TD Cowen: 'Wegovy Injection may be declining'
-
Amazon Pharmacy adds Eli Lilly's Zepbound KwikPen with $299 pricing
-
Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY) following aggregate scripts
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY): "We see ~7% upside to '26 M+Z ests"
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) following Employer Connect launch
-
Lilly launches employer platform for obesity drug access with 15 administrators
-
FDA issues 30 warning letters to telehealth firms over GLP-1 claims
-
CHMP recommends Eli Lilly's Olumiant for teens with severe hair loss
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
Bernstein Weighs In on Eli Lilly (LLY) Amid 'Risk of a Price War'
